Ironwood Pharmaceuticals, Inc. (IRWD) 10-Year Financial Performance & Capital Metrics

IRWD • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsGastrointestinal Therapeutics

AboutIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Show more

Revenue $351M -20.6%
EBITDA $95M +110.1%
Net Income $880K +100.1%
EPS (Diluted) 0.01 +100.1%
Gross Margin 97.85% -0.8%
EBITDA Margin 27.07% +112.7%
Operating Margin 26.5% +112.4%
Net Margin 0.25% +100.1%
ROE -
ROIC 28.7% +113.9%
Debt/Equity -
Interest Coverage 2.82 +106.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 29.4% free cash flow margin
✓Momentum leader: RS Rating 97 (top 3%)
✓High quality earnings: Operating CF exceeds net income
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Profits declining 47.2% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y16.48%

5Y-3.89%

3Y-5.3%

TTM-10.42%

Profit (Net Income) CAGR

10Y-

5Y-47.23%

3Y-88.15%

TTM1259.11%

EPS CAGR

10Y-

5Y-

3Y-88.03%

TTM911.05%

ROCE

10Y Avg-9.33%

5Y Avg-4.87%

3Y Avg-29.21%

Latest36.73%

Peer Comparison

Gastrointestinal Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRWDIronwood Pharmaceuticals, Inc.	735.31M	4.52	821.82	-20.63%	8.42%		14.06%
TAKTakeda Pharmaceutical Company Limited	51.59B	16.33	0.49	7.45%	0.75%	0.46%	100%	0.73
RDHLRedHill Biopharma Ltd.	6.67M	1.31	-0.19	23.17%	-97.52%
EVOKEvoke Pharma, Inc.	18.95M	11.00	-3.91	97.84%	-36.23%	-155.44%		0.73

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	149.56M	273.96M	298.28M	346.64M	428.41M	389.52M	413.75M	410.6M	442.74M	351.41M
Revenue Growth %	0.96%	0.83%	0.09%	0.16%	0.24%	-0.09%	0.06%	-0.01%	0.08%	-0.21%
Cost of Goods Sold+	12K	1.87M	19.41M	32.75M	135.39M	3.14M	70.41M	1.42M	6.15M	7.55M
COGS % of Revenue	0%	0.01%	0.07%	0.09%	0.32%	0.01%	0.17%	0%	0.01%	0.02%
Gross Profit+	149.54M	272.09M	278.87M	313.89M	293.02M	386.39M	343.35M	409.18M	436.59M	343.86M
Gross Margin %	1%	0.99%	0.93%	0.91%	0.68%	0.99%	0.83%	1%	0.99%	0.98%
Gross Profit Growth %	1.94%	0.82%	0.02%	0.13%	-0.07%	0.32%	-0.11%	0.19%	0.07%	-0.21%
Operating Expenses+	233.99M	313.75M	387.56M	415.9M	172.9M	243.45M	111.09M	158.84M	1.38B	250.73M
OpEx % of Revenue	1.56%	1.15%	1.3%	1.2%	0.4%	0.62%	0.27%	0.39%	3.12%	0.71%
Selling, General & Admin	125.25M	173.28M	233.12M	241.29M	0	140M	0	115.99M	0	0
SG&A % of Revenue	0.84%	0.63%	0.78%	0.7%	-	0.36%	-	0.28%	-	-
Research & Development	108.75M	139.49M	148.23M	166.5M	122.24M	88.06M	70.41M	44.27M	116.08M	111.42M
R&D % of Revenue	0.73%	0.51%	0.5%	0.48%	0.29%	0.23%	0.17%	0.11%	0.26%	0.32%
Other Operating Expenses	0	981K	6.21M	8.11M	50.66M	15.38M	40.68M	-1.42M	1.27B	139.31M
Operating Income+	-102.09M	-51.87M	-77.39M	-238.89M	120.12M	142.94M	232.26M	250.34M	-945.43M	93.12M
Operating Margin %	-0.68%	-0.19%	-0.26%	-0.69%	0.28%	0.37%	0.56%	0.61%	-2.14%	0.27%
Operating Income Growth %	0.4%	0.49%	-0.49%	-2.09%	1.5%	0.19%	0.62%	0.08%	-4.78%	1.1%
EBITDA+	-90.46M	-40.61M	-62.77M	-226.92M	125.7M	146.5M	233.78M	251.75M	-943.86M	95.14M
EBITDA Margin %	-0.6%	-0.15%	-0.21%	-0.65%	0.29%	0.38%	0.57%	0.61%	-2.13%	0.27%
EBITDA Growth %	0.42%	0.55%	-0.55%	-2.62%	1.55%	0.17%	0.6%	0.08%	-4.75%	1.1%
D&A (Non-Cash Add-back)	11.63M	11.26M	14.62M	11.97M	5.58M	3.56M	1.52M	1.42M	1.57M	2.01M
EBIT	-111.57M	-42.55M	-18.55M	-156.42M	122.97M	138.34M	232.22M	260.02M	195.84M	95.72M
Net Interest Income+	-30.65M	-37.98M	-34.26M	-34.73M	-33.74M	-27.97M	-30.42M	1.9M	-2.66M	-28.57M
Interest Income	443K	1.17M	2.11M	2.99M	2.86M	1.5M	726K	9.5M	18.97M	4.47M
Interest Expense	31.1M	39.15M	36.37M	37.72M	36.6M	29.48M	31.15M	7.6M	21.63M	33.03M
Other Income/Expense	-40.58M	-29.84M	-71.16M	-43.48M	-61.18M	-34.08M	-31.6M	2.08M	-2.64M	-27.93M
Pretax Income+	-142.67M	-81.71M	-116.94M	-282.37M	58.94M	108.86M	200.66M	252.42M	-948.07M	65.2M
Pretax Margin %	-0.95%	-0.3%	-0.39%	-0.81%	0.14%	0.28%	0.48%	0.61%	-2.14%	0.19%
Income Tax+	0	0	34.26M	-5.75M	0	2.69M	-327.79M	77.36M	83.49M	64.32M
Effective Tax Rate %	1%	1%	1%	1%	0.36%	0.98%	2.63%	0.69%	1.06%	0.01%
Net Income+	-142.67M	-81.71M	-116.94M	-282.37M	21.5M	106.18M	528.45M	175.06M	-1B	880K
Net Margin %	-0.95%	-0.3%	-0.39%	-0.81%	0.05%	0.27%	1.28%	0.43%	-2.26%	0%
Net Income Growth %	0.25%	0.43%	-0.43%	-1.41%	1.08%	3.94%	3.98%	-0.67%	-6.72%	1%
Net Income (Continuing)	-142.67M	-81.71M	-54.91M	-194.15M	58.94M	106.18M	528.45M	175.06M	-1.03B	880K
Discontinued Operations	0	0	0	0	-37.44M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.00	-0.56	-0.78	-1.85	-0.10	0.66	3.21	0.96	-6.45	0.01
EPS Growth %	0.28%	0.44%	-0.39%	-1.37%	0.95%	7.72%	3.86%	-0.7%	-7.72%	1%
EPS (Basic)	-1.00	-0.56	-0.79	-1.85	-0.10	0.67	3.26	1.13	-6.45	0.01
Diluted Shares Outstanding	142.16M	145.91M	148.99M	152.63M	156.02M	160.66M	164.42M	186.31M	155.44M	160.08M
Basic Shares Outstanding	142.16M	144.93M	148.42M	152.63M	156.02M	159.43M	162.25M	154.37M	155.44M	159.08M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	500.2M	380.18M	311.6M	266.44M	306.85M	495.84M	745.23M	780.63M	233.29M	182.37M
Cash & Short-Term Investments	439.39M	305.22M	221.42M	173.17M	177.02M	364.3M	620.13M	656.2M	92.15M	88.56M
Cash Only	261.29M	54M	125.74M	173.17M	177.02M	364.3M	620.13M	656.2M	92.15M	88.56M
Short-Term Investments	178.11M	251.21M	95.68M	0	0	0	0	0	0	0
Accounts Receivable	54.52M	64.85M	82.16M	80.95M	117.25M	122.35M	114.04M	115.46M	129.12M	81.89M
Days Sales Outstanding	133.06	86.41	100.54	85.24	99.89	114.65	100.6	102.64	106.45	85.05
Inventory	0	1.08M	735K	0	648K	0	0	1.25M	0	0
Days Inventory Outstanding	-	211.22	13.82	-	1.75	-	-	321.76	-	-
Other Current Assets	0	0	0	2.1M	1.25M	9.19M	2.37M	0	0	11.92M
Total Non-Current Assets+	118.92M	329.64M	294.08M	65.61M	95.9M	63.4M	381.7M	319.89M	237.78M	168.54M
Property, Plant & Equipment	21.07M	20.51M	17.27M	17.27M	30.17M	25.5M	22.93M	20.31M	18.17M	15.52M
Fixed Asset Turnover	7.10x	13.36x	17.27x	20.07x	14.20x	15.27x	18.05x	20.22x	24.36x	22.64x
Goodwill	0	785K	785K	785K	785K	0	0	0	0	0
Intangible Assets	0	166.12M	159.91M	0	0	0	0	0	3.68M	2.86M
Long-Term Investments	95.21M	140.77M	115.24M	47.45M	0	36.95M	0	15.07M	0	0
Other Non-Current Assets	2.63M	142.22M	116.11M	47.56M	64.94M	943K	358.78M	847K	3.61M	5.92M
Total Assets+	619.12M	709.82M	605.67M	332.05M	402.75M	559.24M	1.13B	1.1B	471.07M	350.91M
Asset Turnover	0.24x	0.39x	0.49x	1.04x	1.06x	0.70x	0.37x	0.37x	0.94x	1.00x
Asset Growth %	0.86%	0.15%	-0.15%	-0.45%	0.21%	0.39%	1.02%	-0.02%	-0.57%	-0.26%
Total Current Liabilities+	76.47M	91.13M	66.03M	119.52M	40.93M	32.17M	161.7M	25.52M	276.1M	38.85M
Accounts Payable	8.59M	17.7M	15.96M	14.89M	5.49M	661K	935K	483K	7.83M	2.13M
Days Payables Outstanding	261.25K	3.46K	300.15	165.96	14.79	76.93	4.85	124.33	464.86	102.8
Short-Term Debt	27.59M	6.23M	4.08M	47.55M	0	3.13M	116.86M	0	199.56M	0
Deferred Revenue (Current)	1000K	1000K	195K	252K	875K	0	0	0	1000K	1000K
Other Current Liabilities	5.02M	42.54M	23.23M	42M	14.89M	14.97M	7.49M	15.88M	26.13M	4.98M
Current Ratio	6.54x	4.17x	4.72x	2.23x	7.50x	15.41x	4.61x	30.58x	0.84x	4.69x
Quick Ratio	6.54x	4.16x	4.71x	2.23x	7.48x	15.41x	4.61x	30.53x	0.84x	4.69x
Cash Conversion Cycle	-	-3.16K	-185.79	-	86.85	-	-	300.07	-	-
Total Non-Current Liabilities+	447.53M	551.97M	529.8M	408.9M	455.07M	464.43M	359.32M	422.62M	541.27M	613.4M
Long-Term Debt	353.89M	366.57M	396.09M	366.14M	407.99M	430.26M	337.33M	396.25M	498.31M	583.99M
Capital Lease Obligations	306K	82K	0	158K	22.08M	20.32M	18.48M	16.6M	14.54M	12.3M
Deferred Tax Liabilities	81.72M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	91.54M	185.32M	133.71M	42.6M	24.99M	13.85M	3.5M	9.77M	28.41M	17.11M
Total Liabilities	524M	643.11M	595.83M	528.42M	496M	496.6M	521.02M	448.14M	817.37M	652.24M
Total Debt+	381.49M	372.8M	400.17M	413.92M	431.22M	453.7M	475.8M	415.92M	715.54M	599.48M
Net Debt	120.2M	318.8M	274.43M	240.75M	254.2M	89.4M	-144.33M	-240.29M	623.38M	510.92M
Debt / Equity	4.01x	5.59x	40.63x	-	-	7.24x	0.79x	0.64x	-	-
Debt / EBITDA	-	-	-	-	3.43x	3.10x	2.04x	1.65x	-	6.30x
Net Debt / EBITDA	-	-	-	-	2.02x	0.61x	-0.62x	-0.95x	-	5.37x
Interest Coverage	-3.28x	-1.32x	-2.13x	-6.33x	3.28x	4.85x	7.46x	32.95x	-43.71x	2.82x
Total Equity+	95.13M	66.72M	9.85M	-196.37M	-93.25M	62.64M	605.91M	652.38M	-346.3M	-301.33M
Equity Growth %	0.07%	-0.3%	-0.85%	-20.94%	0.53%	1.67%	8.67%	0.08%	-1.53%	0.13%
Book Value per Share	0.67	0.46	0.07	-1.29	-0.60	0.39	3.69	3.50	-2.23	-1.88
Total Shareholders' Equity	95.13M	66.72M	9.85M	-196.37M	-93.25M	62.64M	605.91M	652.38M	-346.3M	-301.33M
Common Stock	143K	148K	151K	154K	158K	161K	162K	154K	156K	160K
Retained Earnings	-1.11B	-1.19B	-1.31B	-1.59B	-1.57B	-1.47B	-937.61M	-696.38M	-1.7B	-1.7B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-86K	-7K	-79K	0	-10.08M	0	0	0	-3.03M	923K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-106.93M	-25.43M	-99.56M	-70.88M	10.72M	168.84M	261.89M	273.76M	183.43M	103.55M
Operating CF Margin %	-0.71%	-0.09%	-0.33%	-0.2%	0.03%	0.43%	0.63%	0.67%	0.41%	0.29%
Operating CF Growth %	0.31%	0.76%	-2.91%	0.29%	1.15%	14.74%	0.55%	0.05%	-0.33%	-0.44%
Net Income	-142.67M	-81.71M	-116.94M	-282.37M	21.5M	106.18M	528.45M	175.06M	-1B	880K
Depreciation & Amortization	11.63M	11.26M	14.62M	14.22M	5.58M	3.56M	1.5M	1.42M	1.57M	2.01M
Stock-Based Compensation	25.47M	29.22M	33.82M	43.98M	31.28M	31.18M	22.28M	27.05M	32.01M	29.85M
Deferred Taxes	28.48M	-7.31M	7.53M	159.11M	0	6.6M	-333.29M	65.74M	72.64M	68.09M
Other Non-Cash Items	8.4M	28.12M	-16.81M	-13.44M	52.35M	22.26M	25.23M	1.67M	1.07B	1.98M
Working Capital Changes	-38.24M	-5.02M	-21.79M	7.62M	-99.99M	-941K	17.73M	2.82M	11.28M	739K
Change in Receivables	-28.68M	-10.34M	-17.3M	1.21M	-68.89M	4.09M	7.71M	7.99M	924K	47.24M
Change in Inventory	3.65M	1.27M	346K	-806K	0	648K	0	0	0	0
Change in Payables	-1.55M	19.68M	-6.84M	8.06M	-32.7M	-7.52M	-2.64M	-8.12M	12.38M	-20.21M
Cash from Investing+	-9.15M	-177.67M	151.46M	88.87M	-11.14M	-1.84M	-265K	-136K	-1.03B	-142K
Capital Expenditures	-4.05M	-104.21M	-4.21M	-8.62M	-7.19M	-1.84M	-265K	-136K	-273K	-142K
CapEx % of Revenue	0.03%	0.38%	0.01%	0.02%	0.02%	0%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	147K	-99.78M	135K	1.56M	-3.96M	0	0	0	0	0
Cash from Financing+	303.07M	-4.18M	19.84M	30.07M	-1.19M	18.55M	-4.55M	-237.55M	277.16M	-106.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-18.6M	24.59M	11.08M	31.9M	-20.61M	0	19.58M	9.54M	-29.2M	-2.98M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-110.98M	-129.64M	-103.77M	-79.5M	3.54M	166.99M	261.63M	273.63M	183.15M	103.41M
FCF Margin %	-0.74%	-0.47%	-0.35%	-0.23%	0.01%	0.43%	0.63%	0.67%	0.41%	0.29%
FCF Growth %	0.3%	-0.17%	0.2%	0.23%	1.04%	46.23%	0.57%	0.05%	-0.33%	-0.44%
FCF per Share	-0.78	-0.89	-0.70	-0.52	0.02	1.04	1.59	1.47	1.18	0.65
FCF Conversion (FCF/Net Income)	0.75x	0.31x	0.85x	0.25x	0.50x	1.59x	0.50x	1.56x	-0.18x	117.67x
Interest Paid	0	0	0	0	17.58M	7.22M	7.22M	5.75M	13.55M	32.56M
Taxes Paid	0	0	0	0	0	1.85M	3.45M	4.62M	9.95M	8.41M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-155.35%	-100.97%	-305.46%	-	-	169.5%	158.09%	27.83%	-654.88%	-
Return on Invested Capital (ROIC)	-37.63%	-12.95%	-17.33%	-109.03%	87.75%	68.5%	56.78%	42.98%	-205.77%	28.7%
Gross Margin	99.99%	99.32%	93.49%	90.55%	68.4%	99.19%	82.98%	99.65%	98.61%	97.85%
Net Margin	-95.4%	-29.83%	-39.2%	-81.46%	5.02%	27.26%	127.72%	42.64%	-226.37%	0.25%
Debt / Equity	4.01x	5.59x	40.63x	-	-	7.24x	0.79x	0.64x	-	-
Interest Coverage	-3.28x	-1.32x	-2.13x	-6.33x	3.28x	4.85x	7.46x	32.95x	-43.71x	2.82x
FCF Conversion	0.75x	0.31x	0.85x	0.25x	0.50x	1.59x	0.50x	1.56x	-0.18x	117.67x
Revenue Growth	95.66%	83.18%	8.88%	16.21%	23.59%	-9.08%	6.22%	-0.76%	7.83%	-20.63%

Revenue by Segment

	2014	2017	2018	2019	2020	2021	2022	2023	2024
Collaborative arrangements revenue	-	-	-	-	-	412.78M	410.6M	442.74M	351.41M
Collaborative arrangements revenue Growth	-	-	-	-	-	-	-0.53%	7.83%	-20.63%
Collaborative arrangement, co-promotion agreements	-	-	-	-	-	2.41M	2.19M	2.01M	2.25M
Collaborative arrangement, co-promotion agreements Growth	-	-	-	-	-	-	-9.00%	-8.43%	11.95%
Collaborative arrangement, collaboration and license agreements	-	-	-	-	-	743K	635K	1.8M	1.67M
Collaborative arrangement, collaboration and license agreements Growth	-	-	-	-	-	-	-14.54%	183.31%	-7.00%
Collaborative arrangement, other agreements	-	-	-	-	-	1.75M	1.82M	2.48M	734K
Collaborative arrangement, other agreements Growth	-	-	-	-	-	-	3.93%	35.75%	-70.36%
Royalty	-	-	-	-	100K	-	-	2.2M	400K
Royalty Growth	-	-	-	-	-	-	-	-	-81.82%
Sale of active pharmaceutical ingredient	-	-	-	-	-	969K	-	-	-
Sale of active pharmaceutical ingredient Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Collaboration Agreements	-	-	-	-	32.4M	-	-	-	-
Collaborative Arrangement Collaboration Agreements Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements Upfront Fee	-	-	-	-	10M	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements Upfront Fee Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Co Promotion Agreement	-	-	-	2M	4.3M	-	-	-	-
Collaborative Arrangement Co Promotion Agreement Growth	-	-	-	-	115.10%	-	-	-	-
Collaborative Arrangement Promotion Agreement	-	-	-	3.7M	3.5M	-	-	-	-
Collaborative Arrangement Promotion Agreement Growth	-	-	-	-	-5.41%	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements	-	-	-	-	700K	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Transition Services Agreement	-	-	-	-	600K	-	-	-	-
Collaborative Arrangement Transition Services Agreement Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangements	-	-	-	379.65M	-	-	-	-	-
Collaborative Arrangements Growth	-	-	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient	-	-	70.36M	48.76M	-	-	-	-	-
Active Pharmaceutical Ingredient Growth	-	-	-	-30.69%	-	-	-	-	-
Collaborative Arrangement Other Agreements	-	-	-	1.84M	-	-	-	-	-
Collaborative Arrangement Other Agreements Growth	-	-	-	-	-	-	-	-	-
Product	-	-	3.44M	-	-	-	-	-	-
Product Growth	-	-	-	-	-	-	-	-	-
Lesinurad	-	3.1M	-	-	-	-	-	-	-
Lesinurad Growth	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	-	2.16M	2.3M	2.71M	2.73M	433.24M	343.15M
North America Growth	-	-	-	-	6.34%	18.05%	0.63%	15763.86%	-20.79%
Europe and Other	-	-	-	-	-	2.6M	2.4M	2.8M	3.24M
Europe and Other Growth	-	-	-	-	-	-	-7.69%	16.67%	15.57%
Canada and Mexico	-	-	-	-	-	2.7M	2.7M	-	-
Canada and Mexico Growth	-	-	-	-	-	-	0.00%	-	-
U	-	-	-	325.43M	368.6M	-	-	-	-
U Growth	-	-	-	-	13.27%	-	-	-	-
Canada And Mexico	100K	-	-	2.2M	2.3M	-	-	-	-
Canada And Mexico Growth	-	-	-	-	4.55%	-	-	-	-
Europe	-	-	-	1.7M	2.2M	-	-	-	-
Europe Growth	-	-	-	-	29.41%	-	-	-	-
Europe And Other	-	-	-	1.72M	2.2M	-	-	-	-
Europe And Other Growth	-	-	-	-	27.82%	-	-	-	-
J	-	-	69.6M	27.5M	-	-	-	-	-
J Growth	-	-	-	-60.49%	-	-	-	-	-
China Hong Kong And Macau	-	-	-	200K	-	-	-	-	-
China Hong Kong And Macau Growth	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Ironwood Pharmaceuticals, Inc. (IRWD) reported $339.0M in revenue for fiscal year 2024. This represents a 415% increase from $65.9M in 2011.

Ironwood Pharmaceuticals, Inc. (IRWD) saw revenue decline by 20.6% over the past year.

Yes, Ironwood Pharmaceuticals, Inc. (IRWD) is profitable, generating $28.5M in net income for fiscal year 2024 (0.3% net margin).

Dividend & Returns

Ironwood Pharmaceuticals, Inc. (IRWD) generated $67.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Ironwood Pharmaceuticals, Inc. (IRWD) 10-Year Financial Performance & Capital Metrics

IRWD • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsGastrointestinal Therapeutics

Revenue $351M -20.6%
EBITDA $95M +110.1%
Net Income $880K +100.1%
EPS (Diluted) 0.01 +100.1%
Gross Margin 97.85% -0.8%
EBITDA Margin 27.07% +112.7%
Operating Margin 26.5% +112.4%
Net Margin 0.25% +100.1%
ROE -
ROIC 28.7% +113.9%
Debt/Equity -
Interest Coverage 2.82 +106.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 29.4% free cash flow margin
✓Momentum leader: RS Rating 97 (top 3%)
✓High quality earnings: Operating CF exceeds net income
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Profits declining 47.2% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y16.48%

5Y-3.89%

3Y-5.3%

TTM-10.42%

Profit (Net Income) CAGR

10Y-

5Y-47.23%

3Y-88.15%

TTM1259.11%

EPS CAGR

10Y-

5Y-

3Y-88.03%

TTM911.05%

ROCE

10Y Avg-9.33%

5Y Avg-4.87%

3Y Avg-29.21%

Latest36.73%

Peer Comparison

Gastrointestinal Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRWDIronwood Pharmaceuticals, Inc.	735.31M	4.52	821.82	-20.63%	8.42%		14.06%
TAKTakeda Pharmaceutical Company Limited	51.59B	16.33	0.49	7.45%	0.75%	0.46%	100%	0.73
RDHLRedHill Biopharma Ltd.	6.67M	1.31	-0.19	23.17%	-97.52%
EVOKEvoke Pharma, Inc.	18.95M	11.00	-3.91	97.84%	-36.23%	-155.44%		0.73

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	149.56M	273.96M	298.28M	346.64M	428.41M	389.52M	413.75M	410.6M	442.74M	351.41M
Revenue Growth %	0.96%	0.83%	0.09%	0.16%	0.24%	-0.09%	0.06%	-0.01%	0.08%	-0.21%
Cost of Goods Sold+	12K	1.87M	19.41M	32.75M	135.39M	3.14M	70.41M	1.42M	6.15M	7.55M
COGS % of Revenue	0%	0.01%	0.07%	0.09%	0.32%	0.01%	0.17%	0%	0.01%	0.02%
Gross Profit+	149.54M	272.09M	278.87M	313.89M	293.02M	386.39M	343.35M	409.18M	436.59M	343.86M
Gross Margin %	1%	0.99%	0.93%	0.91%	0.68%	0.99%	0.83%	1%	0.99%	0.98%
Gross Profit Growth %	1.94%	0.82%	0.02%	0.13%	-0.07%	0.32%	-0.11%	0.19%	0.07%	-0.21%
Operating Expenses+	233.99M	313.75M	387.56M	415.9M	172.9M	243.45M	111.09M	158.84M	1.38B	250.73M
OpEx % of Revenue	1.56%	1.15%	1.3%	1.2%	0.4%	0.62%	0.27%	0.39%	3.12%	0.71%
Selling, General & Admin	125.25M	173.28M	233.12M	241.29M	0	140M	0	115.99M	0	0
SG&A % of Revenue	0.84%	0.63%	0.78%	0.7%	-	0.36%	-	0.28%	-	-
Research & Development	108.75M	139.49M	148.23M	166.5M	122.24M	88.06M	70.41M	44.27M	116.08M	111.42M
R&D % of Revenue	0.73%	0.51%	0.5%	0.48%	0.29%	0.23%	0.17%	0.11%	0.26%	0.32%
Other Operating Expenses	0	981K	6.21M	8.11M	50.66M	15.38M	40.68M	-1.42M	1.27B	139.31M
Operating Income+	-102.09M	-51.87M	-77.39M	-238.89M	120.12M	142.94M	232.26M	250.34M	-945.43M	93.12M
Operating Margin %	-0.68%	-0.19%	-0.26%	-0.69%	0.28%	0.37%	0.56%	0.61%	-2.14%	0.27%
Operating Income Growth %	0.4%	0.49%	-0.49%	-2.09%	1.5%	0.19%	0.62%	0.08%	-4.78%	1.1%
EBITDA+	-90.46M	-40.61M	-62.77M	-226.92M	125.7M	146.5M	233.78M	251.75M	-943.86M	95.14M
EBITDA Margin %	-0.6%	-0.15%	-0.21%	-0.65%	0.29%	0.38%	0.57%	0.61%	-2.13%	0.27%
EBITDA Growth %	0.42%	0.55%	-0.55%	-2.62%	1.55%	0.17%	0.6%	0.08%	-4.75%	1.1%
D&A (Non-Cash Add-back)	11.63M	11.26M	14.62M	11.97M	5.58M	3.56M	1.52M	1.42M	1.57M	2.01M
EBIT	-111.57M	-42.55M	-18.55M	-156.42M	122.97M	138.34M	232.22M	260.02M	195.84M	95.72M
Net Interest Income+	-30.65M	-37.98M	-34.26M	-34.73M	-33.74M	-27.97M	-30.42M	1.9M	-2.66M	-28.57M
Interest Income	443K	1.17M	2.11M	2.99M	2.86M	1.5M	726K	9.5M	18.97M	4.47M
Interest Expense	31.1M	39.15M	36.37M	37.72M	36.6M	29.48M	31.15M	7.6M	21.63M	33.03M
Other Income/Expense	-40.58M	-29.84M	-71.16M	-43.48M	-61.18M	-34.08M	-31.6M	2.08M	-2.64M	-27.93M
Pretax Income+	-142.67M	-81.71M	-116.94M	-282.37M	58.94M	108.86M	200.66M	252.42M	-948.07M	65.2M
Pretax Margin %	-0.95%	-0.3%	-0.39%	-0.81%	0.14%	0.28%	0.48%	0.61%	-2.14%	0.19%
Income Tax+	0	0	34.26M	-5.75M	0	2.69M	-327.79M	77.36M	83.49M	64.32M
Effective Tax Rate %	1%	1%	1%	1%	0.36%	0.98%	2.63%	0.69%	1.06%	0.01%
Net Income+	-142.67M	-81.71M	-116.94M	-282.37M	21.5M	106.18M	528.45M	175.06M	-1B	880K
Net Margin %	-0.95%	-0.3%	-0.39%	-0.81%	0.05%	0.27%	1.28%	0.43%	-2.26%	0%
Net Income Growth %	0.25%	0.43%	-0.43%	-1.41%	1.08%	3.94%	3.98%	-0.67%	-6.72%	1%
Net Income (Continuing)	-142.67M	-81.71M	-54.91M	-194.15M	58.94M	106.18M	528.45M	175.06M	-1.03B	880K
Discontinued Operations	0	0	0	0	-37.44M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.00	-0.56	-0.78	-1.85	-0.10	0.66	3.21	0.96	-6.45	0.01
EPS Growth %	0.28%	0.44%	-0.39%	-1.37%	0.95%	7.72%	3.86%	-0.7%	-7.72%	1%
EPS (Basic)	-1.00	-0.56	-0.79	-1.85	-0.10	0.67	3.26	1.13	-6.45	0.01
Diluted Shares Outstanding	142.16M	145.91M	148.99M	152.63M	156.02M	160.66M	164.42M	186.31M	155.44M	160.08M
Basic Shares Outstanding	142.16M	144.93M	148.42M	152.63M	156.02M	159.43M	162.25M	154.37M	155.44M	159.08M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	500.2M	380.18M	311.6M	266.44M	306.85M	495.84M	745.23M	780.63M	233.29M	182.37M
Cash & Short-Term Investments	439.39M	305.22M	221.42M	173.17M	177.02M	364.3M	620.13M	656.2M	92.15M	88.56M
Cash Only	261.29M	54M	125.74M	173.17M	177.02M	364.3M	620.13M	656.2M	92.15M	88.56M
Short-Term Investments	178.11M	251.21M	95.68M	0	0	0	0	0	0	0
Accounts Receivable	54.52M	64.85M	82.16M	80.95M	117.25M	122.35M	114.04M	115.46M	129.12M	81.89M
Days Sales Outstanding	133.06	86.41	100.54	85.24	99.89	114.65	100.6	102.64	106.45	85.05
Inventory	0	1.08M	735K	0	648K	0	0	1.25M	0	0
Days Inventory Outstanding	-	211.22	13.82	-	1.75	-	-	321.76	-	-
Other Current Assets	0	0	0	2.1M	1.25M	9.19M	2.37M	0	0	11.92M
Total Non-Current Assets+	118.92M	329.64M	294.08M	65.61M	95.9M	63.4M	381.7M	319.89M	237.78M	168.54M
Property, Plant & Equipment	21.07M	20.51M	17.27M	17.27M	30.17M	25.5M	22.93M	20.31M	18.17M	15.52M
Fixed Asset Turnover	7.10x	13.36x	17.27x	20.07x	14.20x	15.27x	18.05x	20.22x	24.36x	22.64x
Goodwill	0	785K	785K	785K	785K	0	0	0	0	0
Intangible Assets	0	166.12M	159.91M	0	0	0	0	0	3.68M	2.86M
Long-Term Investments	95.21M	140.77M	115.24M	47.45M	0	36.95M	0	15.07M	0	0
Other Non-Current Assets	2.63M	142.22M	116.11M	47.56M	64.94M	943K	358.78M	847K	3.61M	5.92M
Total Assets+	619.12M	709.82M	605.67M	332.05M	402.75M	559.24M	1.13B	1.1B	471.07M	350.91M
Asset Turnover	0.24x	0.39x	0.49x	1.04x	1.06x	0.70x	0.37x	0.37x	0.94x	1.00x
Asset Growth %	0.86%	0.15%	-0.15%	-0.45%	0.21%	0.39%	1.02%	-0.02%	-0.57%	-0.26%
Total Current Liabilities+	76.47M	91.13M	66.03M	119.52M	40.93M	32.17M	161.7M	25.52M	276.1M	38.85M
Accounts Payable	8.59M	17.7M	15.96M	14.89M	5.49M	661K	935K	483K	7.83M	2.13M
Days Payables Outstanding	261.25K	3.46K	300.15	165.96	14.79	76.93	4.85	124.33	464.86	102.8
Short-Term Debt	27.59M	6.23M	4.08M	47.55M	0	3.13M	116.86M	0	199.56M	0
Deferred Revenue (Current)	1000K	1000K	195K	252K	875K	0	0	0	1000K	1000K
Other Current Liabilities	5.02M	42.54M	23.23M	42M	14.89M	14.97M	7.49M	15.88M	26.13M	4.98M
Current Ratio	6.54x	4.17x	4.72x	2.23x	7.50x	15.41x	4.61x	30.58x	0.84x	4.69x
Quick Ratio	6.54x	4.16x	4.71x	2.23x	7.48x	15.41x	4.61x	30.53x	0.84x	4.69x
Cash Conversion Cycle	-	-3.16K	-185.79	-	86.85	-	-	300.07	-	-
Total Non-Current Liabilities+	447.53M	551.97M	529.8M	408.9M	455.07M	464.43M	359.32M	422.62M	541.27M	613.4M
Long-Term Debt	353.89M	366.57M	396.09M	366.14M	407.99M	430.26M	337.33M	396.25M	498.31M	583.99M
Capital Lease Obligations	306K	82K	0	158K	22.08M	20.32M	18.48M	16.6M	14.54M	12.3M
Deferred Tax Liabilities	81.72M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	91.54M	185.32M	133.71M	42.6M	24.99M	13.85M	3.5M	9.77M	28.41M	17.11M
Total Liabilities	524M	643.11M	595.83M	528.42M	496M	496.6M	521.02M	448.14M	817.37M	652.24M
Total Debt+	381.49M	372.8M	400.17M	413.92M	431.22M	453.7M	475.8M	415.92M	715.54M	599.48M
Net Debt	120.2M	318.8M	274.43M	240.75M	254.2M	89.4M	-144.33M	-240.29M	623.38M	510.92M
Debt / Equity	4.01x	5.59x	40.63x	-	-	7.24x	0.79x	0.64x	-	-
Debt / EBITDA	-	-	-	-	3.43x	3.10x	2.04x	1.65x	-	6.30x
Net Debt / EBITDA	-	-	-	-	2.02x	0.61x	-0.62x	-0.95x	-	5.37x
Interest Coverage	-3.28x	-1.32x	-2.13x	-6.33x	3.28x	4.85x	7.46x	32.95x	-43.71x	2.82x
Total Equity+	95.13M	66.72M	9.85M	-196.37M	-93.25M	62.64M	605.91M	652.38M	-346.3M	-301.33M
Equity Growth %	0.07%	-0.3%	-0.85%	-20.94%	0.53%	1.67%	8.67%	0.08%	-1.53%	0.13%
Book Value per Share	0.67	0.46	0.07	-1.29	-0.60	0.39	3.69	3.50	-2.23	-1.88
Total Shareholders' Equity	95.13M	66.72M	9.85M	-196.37M	-93.25M	62.64M	605.91M	652.38M	-346.3M	-301.33M
Common Stock	143K	148K	151K	154K	158K	161K	162K	154K	156K	160K
Retained Earnings	-1.11B	-1.19B	-1.31B	-1.59B	-1.57B	-1.47B	-937.61M	-696.38M	-1.7B	-1.7B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-86K	-7K	-79K	0	-10.08M	0	0	0	-3.03M	923K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-106.93M	-25.43M	-99.56M	-70.88M	10.72M	168.84M	261.89M	273.76M	183.43M	103.55M
Operating CF Margin %	-0.71%	-0.09%	-0.33%	-0.2%	0.03%	0.43%	0.63%	0.67%	0.41%	0.29%
Operating CF Growth %	0.31%	0.76%	-2.91%	0.29%	1.15%	14.74%	0.55%	0.05%	-0.33%	-0.44%
Net Income	-142.67M	-81.71M	-116.94M	-282.37M	21.5M	106.18M	528.45M	175.06M	-1B	880K
Depreciation & Amortization	11.63M	11.26M	14.62M	14.22M	5.58M	3.56M	1.5M	1.42M	1.57M	2.01M
Stock-Based Compensation	25.47M	29.22M	33.82M	43.98M	31.28M	31.18M	22.28M	27.05M	32.01M	29.85M
Deferred Taxes	28.48M	-7.31M	7.53M	159.11M	0	6.6M	-333.29M	65.74M	72.64M	68.09M
Other Non-Cash Items	8.4M	28.12M	-16.81M	-13.44M	52.35M	22.26M	25.23M	1.67M	1.07B	1.98M
Working Capital Changes	-38.24M	-5.02M	-21.79M	7.62M	-99.99M	-941K	17.73M	2.82M	11.28M	739K
Change in Receivables	-28.68M	-10.34M	-17.3M	1.21M	-68.89M	4.09M	7.71M	7.99M	924K	47.24M
Change in Inventory	3.65M	1.27M	346K	-806K	0	648K	0	0	0	0
Change in Payables	-1.55M	19.68M	-6.84M	8.06M	-32.7M	-7.52M	-2.64M	-8.12M	12.38M	-20.21M
Cash from Investing+	-9.15M	-177.67M	151.46M	88.87M	-11.14M	-1.84M	-265K	-136K	-1.03B	-142K
Capital Expenditures	-4.05M	-104.21M	-4.21M	-8.62M	-7.19M	-1.84M	-265K	-136K	-273K	-142K
CapEx % of Revenue	0.03%	0.38%	0.01%	0.02%	0.02%	0%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	147K	-99.78M	135K	1.56M	-3.96M	0	0	0	0	0
Cash from Financing+	303.07M	-4.18M	19.84M	30.07M	-1.19M	18.55M	-4.55M	-237.55M	277.16M	-106.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-18.6M	24.59M	11.08M	31.9M	-20.61M	0	19.58M	9.54M	-29.2M	-2.98M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-110.98M	-129.64M	-103.77M	-79.5M	3.54M	166.99M	261.63M	273.63M	183.15M	103.41M
FCF Margin %	-0.74%	-0.47%	-0.35%	-0.23%	0.01%	0.43%	0.63%	0.67%	0.41%	0.29%
FCF Growth %	0.3%	-0.17%	0.2%	0.23%	1.04%	46.23%	0.57%	0.05%	-0.33%	-0.44%
FCF per Share	-0.78	-0.89	-0.70	-0.52	0.02	1.04	1.59	1.47	1.18	0.65
FCF Conversion (FCF/Net Income)	0.75x	0.31x	0.85x	0.25x	0.50x	1.59x	0.50x	1.56x	-0.18x	117.67x
Interest Paid	0	0	0	0	17.58M	7.22M	7.22M	5.75M	13.55M	32.56M
Taxes Paid	0	0	0	0	0	1.85M	3.45M	4.62M	9.95M	8.41M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-155.35%	-100.97%	-305.46%	-	-	169.5%	158.09%	27.83%	-654.88%	-
Return on Invested Capital (ROIC)	-37.63%	-12.95%	-17.33%	-109.03%	87.75%	68.5%	56.78%	42.98%	-205.77%	28.7%
Gross Margin	99.99%	99.32%	93.49%	90.55%	68.4%	99.19%	82.98%	99.65%	98.61%	97.85%
Net Margin	-95.4%	-29.83%	-39.2%	-81.46%	5.02%	27.26%	127.72%	42.64%	-226.37%	0.25%
Debt / Equity	4.01x	5.59x	40.63x	-	-	7.24x	0.79x	0.64x	-	-
Interest Coverage	-3.28x	-1.32x	-2.13x	-6.33x	3.28x	4.85x	7.46x	32.95x	-43.71x	2.82x
FCF Conversion	0.75x	0.31x	0.85x	0.25x	0.50x	1.59x	0.50x	1.56x	-0.18x	117.67x
Revenue Growth	95.66%	83.18%	8.88%	16.21%	23.59%	-9.08%	6.22%	-0.76%	7.83%	-20.63%

Revenue by Segment

	2014	2017	2018	2019	2020	2021	2022	2023	2024
Collaborative arrangements revenue	-	-	-	-	-	412.78M	410.6M	442.74M	351.41M
Collaborative arrangements revenue Growth	-	-	-	-	-	-	-0.53%	7.83%	-20.63%
Collaborative arrangement, co-promotion agreements	-	-	-	-	-	2.41M	2.19M	2.01M	2.25M
Collaborative arrangement, co-promotion agreements Growth	-	-	-	-	-	-	-9.00%	-8.43%	11.95%
Collaborative arrangement, collaboration and license agreements	-	-	-	-	-	743K	635K	1.8M	1.67M
Collaborative arrangement, collaboration and license agreements Growth	-	-	-	-	-	-	-14.54%	183.31%	-7.00%
Collaborative arrangement, other agreements	-	-	-	-	-	1.75M	1.82M	2.48M	734K
Collaborative arrangement, other agreements Growth	-	-	-	-	-	-	3.93%	35.75%	-70.36%
Royalty	-	-	-	-	100K	-	-	2.2M	400K
Royalty Growth	-	-	-	-	-	-	-	-	-81.82%
Sale of active pharmaceutical ingredient	-	-	-	-	-	969K	-	-	-
Sale of active pharmaceutical ingredient Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Collaboration Agreements	-	-	-	-	32.4M	-	-	-	-
Collaborative Arrangement Collaboration Agreements Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements Upfront Fee	-	-	-	-	10M	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements Upfront Fee Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Co Promotion Agreement	-	-	-	2M	4.3M	-	-	-	-
Collaborative Arrangement Co Promotion Agreement Growth	-	-	-	-	115.10%	-	-	-	-
Collaborative Arrangement Promotion Agreement	-	-	-	3.7M	3.5M	-	-	-	-
Collaborative Arrangement Promotion Agreement Growth	-	-	-	-	-5.41%	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements	-	-	-	-	700K	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Transition Services Agreement	-	-	-	-	600K	-	-	-	-
Collaborative Arrangement Transition Services Agreement Growth	-	-	-	-	-	-	-	-	-
Collaborative Arrangements	-	-	-	379.65M	-	-	-	-	-
Collaborative Arrangements Growth	-	-	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient	-	-	70.36M	48.76M	-	-	-	-	-
Active Pharmaceutical Ingredient Growth	-	-	-	-30.69%	-	-	-	-	-
Collaborative Arrangement Other Agreements	-	-	-	1.84M	-	-	-	-	-
Collaborative Arrangement Other Agreements Growth	-	-	-	-	-	-	-	-	-
Product	-	-	3.44M	-	-	-	-	-	-
Product Growth	-	-	-	-	-	-	-	-	-
Lesinurad	-	3.1M	-	-	-	-	-	-	-
Lesinurad Growth	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	-	2.16M	2.3M	2.71M	2.73M	433.24M	343.15M
North America Growth	-	-	-	-	6.34%	18.05%	0.63%	15763.86%	-20.79%
Europe and Other	-	-	-	-	-	2.6M	2.4M	2.8M	3.24M
Europe and Other Growth	-	-	-	-	-	-	-7.69%	16.67%	15.57%
Canada and Mexico	-	-	-	-	-	2.7M	2.7M	-	-
Canada and Mexico Growth	-	-	-	-	-	-	0.00%	-	-
U	-	-	-	325.43M	368.6M	-	-	-	-
U Growth	-	-	-	-	13.27%	-	-	-	-
Canada And Mexico	100K	-	-	2.2M	2.3M	-	-	-	-
Canada And Mexico Growth	-	-	-	-	4.55%	-	-	-	-
Europe	-	-	-	1.7M	2.2M	-	-	-	-
Europe Growth	-	-	-	-	29.41%	-	-	-	-
Europe And Other	-	-	-	1.72M	2.2M	-	-	-	-
Europe And Other Growth	-	-	-	-	27.82%	-	-	-	-
J	-	-	69.6M	27.5M	-	-	-	-	-
J Growth	-	-	-	-60.49%	-	-	-	-	-
China Hong Kong And Macau	-	-	-	200K	-	-	-	-	-
China Hong Kong And Macau Growth	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Ironwood Pharmaceuticals, Inc. (IRWD) reported $339.0M in revenue for fiscal year 2024. This represents a 415% increase from $65.9M in 2011.

Ironwood Pharmaceuticals, Inc. (IRWD) saw revenue decline by 20.6% over the past year.

Yes, Ironwood Pharmaceuticals, Inc. (IRWD) is profitable, generating $28.5M in net income for fiscal year 2024 (0.3% net margin).

Dividend & Returns

Ironwood Pharmaceuticals, Inc. (IRWD) generated $67.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.